ÂÜÀòÂÒÂ×

Dr. Mace Rothenberg has more than three decades of experience in medical oncology, academic research and biopharmaceutical industry leadership. He served as chief medical officer of Pfizer from 2019 to 2021 and before that led Pfizer’s oncology development organization for 10 years. During that time, his organization at Pfizer developed and obtained regulatory approvals for 11 new cancer medicines, including Ibrance® (palbociclib), the first CDK 4/6 inhibitor for patients with HR+/HER2- advanced breast cancer, and Xalkori® (crizotinib), the first targeted medicine developed for patients with ALK+ non-small cell lung cancer. Before joining Pfizer, Dr. Rothenberg served on the faculties of Vanderbilt University Medical Center and the University of Texas Health Science Center-San Antonio. He has received numerous awards recognizing his accomplishments in oncology research and development and his years of service to cancer patients, including the American Cancer Society’s Lane W. Adams Quality of Life Award and the American Society of Clinical Oncology’s Statesman Award.

Dr. Rothenberg is a member of the American College of Physicians and the American Society of Clinical Oncology and is board-certified in internal medicine and medical oncology. He currently also serves on the board of Tango Therapeutics. Dr. Rothenberg received an M.D. from New York University School of Medicine, followed by a residency in internal medicine at Vanderbilt University and a fellowship in medical oncology at the National Cancer Institute.